Immune Responses of a Designed HIV-1 DNA Vaccine on Rhesus Monkeys

Overview

Journal Chin Sci Bull

Specialty Science

Date 2020 Mar 28

PMID 32214722

Authors

Lishu Zhang

Jin Ningyi

Song Yingjin

Sun Yansong

Wang Hong

Zhan Dawei

Hewen Ma

Yupu Shang

Hongtao Jin

Baoqing Hong

Chang Li

Affiliations

Soon will be listed here.

Abstract

An effective HIV-1 vaccine will be the ultimate solution for the prevention of HIV/AIDS, though HAART plays important roles in treating the disease. In this study, a large-scale recombinant DNA plasmid containing a designed HIV-1 multi-epitope-p24 chimeric gene was prepared and purified. Rhesus monkeys were then inoculated muscularly with the plasmid for four times in week 0, 4, 8 and 18. Whole blood was collected two weeks after the third and fourth inoculation, followed by serum and peripheral blood mononuclear cell (PBMC) separation. The CTL activity and proliferation of PBMCs stimulated by macaque MHC-I-restricted HIV-1 CTL epitope peptide were analyzed by MTT and LDH release assay, respectively. Th1 cytokines in supernatant of cultured PBMC stimulated by HIV-1 CTL epitope peptide and anti-HIV-1 antibody in serum were assayed by ELISA. The results showed that increased CTL target-killing activity, higher secretion of Th1 cytokines (IFN-γ and IL-2) and promoted proliferative reaction of monkey PBMCs stimulated by HIV-1 CTL epitope peptide were detected in the immunization group inoculated by the recombinant DNA vaccine for three times, which were further enhanced by the fourth inoculation. At the same time, HIV-1 specific antibody in serum of immunized monkeys was higher than that in controls. We concluded that the designed HIV-1 DNA vaccine may induce HIV-1 specific cellular and humoral immunity on monkeys.

References

Gaschen B, Taylor J, Yusim K, Foley B, Gao F, Lang D . Diversity considerations in HIV-1 vaccine selection. Science. 2002; 296(5577):2354-60. DOI: 10.1126/science.1070441. View

Borrow P, Lewicki H, Hahn B, Shaw G, Oldstone M . Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol. 1994; 68(9):6103-10. PMC: 237022. DOI: 10.1128/JVI.68.9.6103-6110.1994. View

Adorini L, Sinigaglia F . Pathogenesis and immunotherapy of autoimmune diseases. Immunol Today. 1997; 18(5):209-11. DOI: 10.1016/s0167-5699(97)01031-1. View

Novitsky V, Smith U, Gilbert P, McLane M, Chigwedere P, Williamson C . Human immunodeficiency virus type 1 subtype C molecular phylogeny: consensus sequence for an AIDS vaccine design?. J Virol. 2002; 76(11):5435-51. PMC: 137027. DOI: 10.1128/jvi.76.11.5435-5451.2002. View

Peng J, Tong G, Wang Y, Qiu H . [Multi-epitope DNA vaccines against avian influenza in chickens]. Sheng Wu Gong Cheng Xue Bao. 2005; 19(5):623-7. View

Horton H, Vogel T, Carter D, Vielhuber K, Fuller D, Shipley T . Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression.... J Virol. 2002; 76(14):7187-202. PMC: 136301. DOI: 10.1128/jvi.76.14.7187-7202.2002. View

Chouquet C, Autran B, Gomard E, Calvez V, Katlama C, Costagliola D . Correlation between breadth of memory HIV-specific cytotoxic T cells, viral load and disease progression in HIV infection. AIDS. 2002; 16(18):2399-407. DOI: 10.1097/00002030-200212060-00004. View

Walker B, Korber B . Immune control of HIV: the obstacles of HLA and viral diversity. Nat Immunol. 2001; 2(6):473-5. DOI: 10.1038/88656. View

Rosenberg E, Billingsley J, Caliendo A, Boswell S, Sax P, Kalams S . Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science. 1997; 278(5342):1447-50. DOI: 10.1126/science.278.5342.1447. View

10.

Stebbings R, Berry N, Stott J, Hull R, Walker B, Lines J . Vaccination with live attenuated simian immunodeficiency virus for 21 days protects against superinfection. Virology. 2004; 330(1):249-60. DOI: 10.1016/j.virol.2004.09.026. View

11.

Vogel T, Friedrich T, OConnor D, Rehrauer W, Dodds E, Hickman H . Escape in one of two cytotoxic T-lymphocyte epitopes bound by a high-frequency major histocompatibility complex class I molecule, Mamu-A*02: a paradigm for virus evolution and persistence?. J Virol. 2002; 76(22):11623-36. PMC: 136802. DOI: 10.1128/jvi.76.22.11623-11636.2002. View

12.

Daniel M, Kirchhoff F, Czajak S, Sehgal P, Desrosiers R . Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science. 1992; 258(5090):1938-41. DOI: 10.1126/science.1470917. View

13.

Nacsa J, Stanton J, Kunstman K, Tsai W, Watkins D, Wolinsky S . Emergence of cytotoxic T lymphocyte escape mutants following antiretroviral treatment suspension in rhesus macaques infected with SIVmac251. Virology. 2002; 305(1):210-8. DOI: 10.1006/viro.2002.1753. View

14.

Walmsley S, Bernstein B, King M, Arribas J, Beall G, Ruane P . Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med. 2002; 346(26):2039-46. DOI: 10.1056/NEJMoa012354. View

15.

Gea-Banacloche J, Migueles S, Martino L, Shupert W, McNeil A, Sabbaghian M . Maintenance of large numbers of virus-specific CD8+ T cells in HIV-infected progressors and long-term nonprogressors. J Immunol. 2000; 165(2):1082-92. DOI: 10.4049/jimmunol.165.2.1082. View

16.

Shiver J, Fu T, Chen L, Casimiro D, Davies M, Evans R . Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature. 2002; 415(6869):331-5. DOI: 10.1038/415331a. View

17.

Clerici M, Sarin A, Coffman R, Wynn T, Blatt S, Hendrix C . Type 1/type 2 cytokine modulation of T-cell programmed cell death as a model for human immunodeficiency virus pathogenesis. Proc Natl Acad Sci U S A. 1994; 91(25):11811-5. PMC: 45325. DOI: 10.1073/pnas.91.25.11811. View

18.

Smith S, Khoroshev M, Marx P, Orenstein J, Jeang K . Constitutively dead, conditionally live HIV-1 genomes. Ex vivo implications for a live virus vaccine. J Biol Chem. 2001; 276(34):32184-90. DOI: 10.1074/jbc.M101604200. View

19.

Palella Jr F, Delaney K, Moorman A, Loveless M, Fuhrer J, Satten G . Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998; 338(13):853-60. DOI: 10.1056/NEJM199803263381301. View

20.

Amara R, Villinger F, Altman J, Lydy S, ONeil S, Staprans S . Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science. 2001; 292(5514):69-74. DOI: 10.1126/science.1058915. View